INDIANAPOLIS, June 1, 2018 /PRNewswire/
-- Eli Lilly and Company (NYSE: LLY) announced
that it will present new data evaluating mirikizumab for the
treatment of moderate-to-severe ulcerative colitis (UC) at
Digestive Disease Week (DDW), taking place June 2-5, 2018, in Washington, D.C.
Mirikizumab is an investigational IL-23p19 monoclonal antibody.
Lilly is conducting two Phase 2 trials evaluating mirikizumab for
the treatment of moderate-to-severe UC and Crohn's disease
(CD).
The Phase 2 safety and efficacy results for mirikizumab, which
will be presented from the podium on June
5 at DDW, will be the first public disclosure related to
IL-23p19 treatment of moderate-to-severe UC. In addition to the
podium presentation, Lilly will release three poster presentations
detailing real world experience for patients with UC and CD, as
well as data on the burden of worsening symptoms for patients with
UC.
"Millions of people globally are affected by inflammatory bowel
diseases such as ulcerative colitis and Crohn's disease, and many
are still looking for a treatment that works for them–particularly
one that addresses the life-altering symptoms of UC," said Lotus
Mallbris, M.D., vice president, immunology platform team leader,
Lilly Bio-Medicines. "At Lilly, we are committed to identifying new
ways to deliver outcomes that meet the needs of people living with
these challenging diseases. We are proud to present these data at
DDW and look forward to continuing the ongoing clinical research
and development of mirikizumab as a potential treatment for
inflammatory diseases, including UC, psoriasis and Crohn's
disease."
The podium presentation and posters to be presented are
highlighted below:
Tuesday, June 5
- Abstract #882: 10:15-10:30 a.m.
ET, Room 146A
-
- Efficacy and Safety of Anti-Interleukin-23 Therapy with
Mirikizumab (LY3074828) in Patients with Moderate-To-Severe
Ulcerative Colitis in a Phase 2 Study
- Presenter: William J. Sandborn,
University California San Diego, La
Jolla, CA, United
States
Posters
- Abstract #1914: Real World Use of Oral Corticosteroids
≥30mg/Day: Characteristics of Users with Newly Diagnosed Crohn's
Disease
- Abstract #1915: Real World Use of Oral Corticosteroids ≥30
Mg/Day: Characteristics of Users with Newly Diagnosed Ulcerative
Colitis
- Abstract #1935: The Burden Associated with Temporal Worsening
of Symptoms from the UC Patient Perspective
About Mirikizumab
Mirikizumab is a humanized IgG4
monoclonal antibody that binds to the p19 subunit of interleukin
23. Mirikizumab is being studied for the treatment of immune
mediated inflammatory diseases including psoriasis, Ulcerative
Colitis and Crohn's Disease.
About Ulcerative Colitis
Ulcerative colitis (UC) is a
chronic inflammatory bowel disease that affects the colon.[1] UC
occurs when the immune system sends white blood cells into the
lining of the intestines, where they produce chronic inflammation
and ulcerations.1 UC affects millions of patients globally.[2]
Early and sustained symptom relief, improvement in the appearance
of the mucosa, and clinical remission are important treatment goals
for healthcare providers and patients.2 There is an unmet need for
treatment options for UC that provide meaningful symptom relief and
deliver sustained clinical remission.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the
globe, Lilly employees work to discover and bring
life-changing medicines to those who need them, improve the
understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us
at www.lilly.com and www.lilly.com/newsroom/social-channels. P-LLY
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about mirikizumab as a potential treatment for patients with
ulcerative colitis and Crohn's disease, and reflects Lilly's
current belief. As with any pharmaceutical product, there are
substantial risks and uncertainties in the process of development
and commercialization. Among other things, there can be no
guarantee that future study results will be consistent with the
results to date, that mirikizumab will receive regulatory
approvals, or be commercially successful. For further discussion of
these and other risks and uncertainties, see Lilly's most recent
Form 10-K and Form 10-Q filings with the United States Securities
and Exchange Commission. Except as required by law, Lilly
undertakes no duty to update forward-looking statements to reflect
events after the date of this release.
____________________________
1 What is Ulcerative Colitis? Crohn's and Colitis
Foundation Website.
http://www.crohnscolitisfoundation.org/what-are-crohns-and-colitis/what-is-ulcerative-colitis/.
Accessed June 1, 2018.
2 Adelphi Data 2017.
Refer
to:
|
Danielle Neveles,
danielle.neveles@lilly.com; 317-796-4564 (Lilly media)
|
|
Brianna Wilkins;
brianna.wilkins@edelman.com; 312-375-7495 (Media)
|
|
Kevin Hern;
hern_kevin_r@lilly.com; 317-277-1838 (Lilly investors)
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/lilly-to-showcase-new-data-at-digestive-disease-week-2018-for-mirikizumab-in-moderate-to-severe-ulcerative-colitis-300657940.html
SOURCE Eli Lilly & Company